Get the latest crypto news, updates, and reports by subscribing to our free newsletter.
Giấy phép số 4978/GP-TTĐT do Sở Thông tin và Truyền thông Hà Nội cấp ngày 14 tháng 10 năm 2019 / Giấy phép SĐ, BS GP ICP số 2107/GP-TTĐT do Sở TTTT Hà Nội cấp ngày 13/7/2022.
© 2026 Index.vn
The U.S. added an estimated 178,000 jobs in March, rebounding from unexpectedly large job losses in February, according to data released Friday morning. March’s gains were about three times what economists expected, and the unemployment rate edged down to 4.3%. Why the March jobs report matters Market watchers generally viewed…
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and reminds investors of the May 4, 2026 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. James (Josh) Wilson, Faruqi & Faruqi Senior Partner, represents the firm in this matter. Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia, and the firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com. As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false or misleading statements and/or failing to disclose the true state of Aquestive's NDA for Anaphylm and by concealing or downplaying the significance of the human factors involved in the use of its sublingual film, such as packaging, administration, and labeling. On January 9, 2026, Aquestive's President and Chief Executive Officer announced that during its ongoing review of the Company's NDA for Anaphylm, the FDA notified the Company that it had identified deficiencies in the NDA that preclude discussion of labeling and post-marketing commitments at this time, and that the notification did not specify the deficiencies. On this news, Aquestive's stock price fell 37.04%, to close at $3.91 per share on January 9, 2026. The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members to direct the litigation. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may remain an absent member. Your ability to share in any recovery is not affected by the decision to serve as lead plaintiff or not. Faruqi & Faruqi, LLP also encourages anyone with information regarding Aquestive's conduct to contact the firm, including whistleblowers, former employees, shareholders and others. To learn more about the Aquestive Therapeutics class action, go to www.faruqilaw.com/AQST or call Faruqi & Faruqi directly. Follow us for updates on LinkedIn, X, or Facebook. Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP. Prior results do not guarantee or predict a similar outcome. All communications will be treated in a confidential manner.
In brief\n\nBitcoin dropped to about $93,000, falling back below the EMA50 and putting its recent golden cross at risk of invalidation. The global crypto market cap stands at $3.15 trillion, down 2.38% in 24 hours. On Myriad Markets, 82% of the money is betting on Bitcoin pumping to $100K before…
